Eprodisate (disodium)

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: Eprodisate (disodium)
• 英文别名: disodium;propane-1,3-disulfonate
• 化学式: C3H6Na2O6S2
• 分子量: 248.2
• InChiKey: DKGJFKPIUSHDIT-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -7.53
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  131
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  丙烯磺酸 、 sodium hydrogensulfite 生成 Eprodisate (disodium)
  参考文献：
  名称：

  OHME, ROLAND;BALLSCHUH, DETLEF;WIHSMANN, MARC

  摘要：

  DOI：

文献信息

• Method for treating amyloidosis
  申请人：Queen's University at Kingston

  公开号：US20040208875A1

  公开（公告）日：2004-10-21

  Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

  本文描述了治疗化合物和方法，用于抑制主体中的淀粉样沉积物，无论其临床设置如何。通过向主体内注射含有阴离子基团和载体分子的治疗化合物的有效剂量，或其药学上可接受的盐，从而抑制淀粉样沉积物的形成，从而抑制淀粉样蛋白与基底膜成分之间的相互作用。首选阴离子基团为磺酸盐和硫酸盐。首选载体分子包括碳水化合物、聚合物、肽、肽衍生物、脂肪基团、脂环基团、杂环基团、芳香基团和其组合。
• Sulfonated compounds and compositions for treating amyloidosis
  申请人：Bellus Health (International) Limited

  公开号：US07754761B2

  公开（公告）日：2010-07-13

  Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

  本文描述了用于抑制主体中淀粉样沉积的治疗化合物和方法，无论其临床设置如何。通过向主体注射包含阴离子基团和载体分子的治疗化合物或其药学上可接受的盐的有效量，抑制淀粉样沉积，从而抑制淀粉样蛋白与基底膜成分之间的相互作用。首选的阴离子基团是磺酸盐和硫酸盐。首选的载体分子包括碳水化合物、聚合物、肽、肽衍生物、脂肪基团、脂环基团、杂环基团、芳香基团和其组合。
• METHOD FOR TREATING AMYLOIDOSIS
  申请人：Kisilevsky Robert

  公开号：US20110002875A1

  公开（公告）日：2011-01-06

  Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

  本文描述了治疗化合物和方法，用于抑制患者体内的淀粉样沉积，无论其临床情况如何。通过向患者施用含有阴离子基团和载体分子的治疗化合物或其药学上可接受的盐的有效量，从而抑制淀粉样沉积，以抑制淀粉样蛋白与基底膜成分之间的相互作用。首选阴离子基团为磺酸盐和硫酸盐。首选载体分子包括碳水化合物、聚合物、肽、肽衍生物、脂肪基团、脂环基团、杂环基团、芳香基团和其组合。

表征谱图